Janssen Research & Development
1400 McKean Road
About Janssen Research & DevelopmentAt Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.
As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research. The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
41 articles with Janssen Research & Development
GeneCentric Therapeutics Enters into Research Collaboration with Janssen on Genomic Drug Response Biomarkers for Non-Muscle Invasive Bladder Cancer
GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric’s advanced RNA-based molecular profiling platform to elucidate poten
The Industrial Macromolecular Crystallography Association, an association of pharmaceutical companies that leverages the power of high-energy X-rays to accelerate structural biology research for drug discovery, announced that Janssen Research & Development, LLC has joined IMCA.
IMMUNOPRECISE ANTIBODIES LTD., a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has entered into a research license agreement with Janssen Research & Development, LLC, providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target.
An oral, gut-restricted IL-23 receptor antagonist peptide is successfully nominated as a second-generation development candidate, advancing the collaboration and triggering a $5M milestone payment
Target Discovery and Therapeutic Validation Collaboration is Resonant’s First Announced Deal
MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC issued a press release to report the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of Tremfya for the treatment of adult patients with active psoriatic arthritis.
ADS to provide expertise and capabilities in antibody drug discovery
Resolution Advancing Development of Cell-Free DNA Companion Diagnostic for Prostate Cancer through Collaboration with Janssen
Liquid biopsy assay with recent Breakthrough Device Designation from FDA is being used to screen patients with prostate cancer for HRD mutations and deletions as part of phase II and III clinical studies
Companies to share proteomic and clinical data to drive new drug discovery and development, and precision health management
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC (Janssen), has further expanded the clinical development of guselkumab (Tremfya(R)) into ulcerative colitis (UC).
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa
MorphoSys AG announced today that its licensee Janssen Research & Development, LLC (Janssen) initiated a phase 2 clinical study of guselkumab in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease also known as acne inversa.
Johnson & Johnson Innovation Launches Reimagining Respiratory Protection QuickFire Challenge in Collaboration with the U.S. Department of Health and Human Services
Johnson & Johnson Innovation, JLABS teams with the Biomedical Advanced Research and Development Authority (BARDA) to advance new technologies to improve global pandemic preparedness against respiratory infection outbreaks
Hemogenyx Pharmaceuticals Plc announces that its wholly owned subsidiary, Immugenyx, LLC (“Immugenyx”), has entered into a collaboration agreement with Janssen Research & Development, LLC (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation LLC.
Janssen to supply PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737
Janssen R&D's New Data for DARZALEX (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
Janssen R&D today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX had a manageable safety profile and a 12 percent rate of infusion reactions in patients with relapsed or refractory multiple myeloma.
Janseen Biotech Release: DARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible
Janssen R&D today announced data from the Phase 3 ALCYONE study, showing that DARZALEX in combination with bortezomib, melphalan and prednisone significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for ASCT.
Sustained Benefit in Patients With Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3 1/2 -Year Follow-Up Data of IMBRUVICA (ibrutinib)
The extended follow-up data demonstrated that patients treated with IMBRUVICA earlier (after first relapse) experienced the best clinical outcomes, in terms of both efficacy and tolerability.
Janssen Submits Supplemental NDA to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients With Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
This application is based on data from the landmark COMPASS study, the only randomized trial to investigate a Factor Xa inhibitor for preventing major CV events in this population.
Janssen's New Real-World Analysis Shows INVOKANA (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines
A new real-world analysis of adults with type 2 diabetes and established CVD shows adult patients who initiated therapy with INVOKANA or another SGLT2i had a 43 percent reduced risk for ACM and hospitalization for HHF after an average of 1.6 years, compared to similar patients who initiated treatment with a non-SGLT2i medication using an ITT approach.
Janssen R&D's INVOKANA (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
INVOKANA also achieved similar and proportional risk reductions for hospitalization due to heart failure and renal outcomes in each of the primary and secondary prevention groups.